Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ga Bombesin PET/CT (NeoB) Imaging for Staging ER/PR+ HER2- Metastatic Breast Cancer
NCT05889728Phase 2Completed
- Sponsor
- St Vincent's Hospital
- Start
- Feb 2023
- Primary completion
- Feb 2025
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gallium Ga 68 DOTA-NeoBOMB1 in breast cancer, sponsored by St Vincent's Hospital. Primary endpoint: Assessment of Diagnostic Accuracy using a standard of truth at 2 years. Started Feb 2023; status: completed.
02
Drugs
gallium Ga 68 DOTA-NeoBOMB1
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05889728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05889728.